OncoMatch/Clinical Trials/NCT07116057
MOv19-BBz CAR T Cells in FRa+ Cancers
Is NCT07116057 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including MOv19-BBz CAR T cells and Cyclophosphamide/Fludarabine for metastatic non small cell lung cancer.
Treatment: MOv19-BBz CAR T cells · Cyclophosphamide/Fludarabine · FRa Expression Testing — This is a Phase I open-label clinical trial to assess the safety, feasibility, and preliminary efficacy of intrapleural administration of MOv19-BBz CAR T cells in patients with FRa+ cancers. This study will be initiated in patients with metastatic or recurrent non-small cell lung cancer (NSCLC) only. Subjects will receive a single dose of MOv19-BBz CAR T cells via intrapleural infusion following lymphodepleting chemotherapy. Subjects without an existing intra-pleural catheter will have a temporary pleural catheter placed for the study. Subjects may initiate treatment with commercial checkpoint inhibitors per routine care beginning at least 28 days after receiving MOv19-BBz CAR T cells.
Check if I qualifyExtracted eligibility criteria
Cancer type
Small Cell Lung Cancer
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: FOLR1 overexpression (≥ 10% of tumor cells by IHC)
Documentation of tumor FRa expression by IHC at the Hospital of the University of Pennsylvania (≥ 10% of tumor cells)
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Lab requirements
Kidney function
Serum creatinine ≤ 1.5 mg/dl or creatinine clearance ≥ 30 cc/min; not on dialysis
Liver function
ALT/AST ≤ 3x upper limit of normal range; Serum total bilirubin ≤ 1.5 mg/dl, unless Gilbert's syndrome (≤ 3.0 mg/dl)
Cardiac function
Left Ventricle Ejection Fraction (LVEF) ≥ 40% confirmed by ECHO or MUGA
Adequate organ function defined as: Serum creatinine ≤ 1.5 mg/dl or creatinine clearance ≥ 30 cc/min; Patient must not be on dialysis; ALT/AST ≤ 3x upper limit of normal range; Serum total bilirubin ≤ 1.5 mg/dl, unless the subject has Gilbert's syndrome (if so, serum total bilirubin must be ≤ 3.0 mg/dl); Must have a minimum level of pulmonary reserve defined as < Grade 1 dyspnea and pulse oxygen > 92% on room air; Left Ventricle Ejection Fraction (LVEF) ≥ 40% confirmed by ECHO or MUGA
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Pennsylvania · Philadelphia, Pennsylvania
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify